Education
About Us
Working with TipRanks
Follow Us
Pds Biotechnology (PDSB)
:PDSB
PDSB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.85 - $4.03
Previous CloseN/A
Volume197.50K
Average Volume (3M)568.58K
Market Cap
$47.97M
Enterprise Value$47.71M
Total Cash (Recent Filing)$31.87M
Total Debt (Recent Filing)$18.54M
Price to Earnings (P/E)―
Beta2.48
Next Earnings
Nov 12, 2025EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding47,025,500
10 Day Avg. Volume416,555
30 Day Avg. Volume568,575
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)3.13
Price to Sales (P/S)0.00
P/FCF Ratio-1.69
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue807.80
Enterprise Value/Gross Profit-3.01K
Enterprise Value/Ebitda-1.47
Forecast
1Y Price Target
$13.00Price Target Upside1174.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementsPDS01ADC could represent a significant advancement in solid tumor intervention, while also being a notable commercial and value generating opportunity for PDS and investors.
Clinical TrialsThe colorectal cancer cohort of the Phase 2 PDS01ADC study met criteria for expansion into Stage 2 following encouraging Stage 1 results.
Market PotentialThe prevalence of HPV16 in U.S. R/M HNSCC is estimated at 40-60%, with U.S. and EU prevalence expected to exceed 60%, highlighting the substantial market for effective treatments.
Bears Say
Public Health ChallengesHPV16+ remains the most prominent and rapidly growing issue in HNSCC, with its incidence expected to continue rising over the next 20-30 years, indicating a significant and expanding public health issue.
PDS Biotechnology News
PDSB FAQ
What was Pds Biotechnology’s price range in the past 12 months?
Pds Biotechnology lowest stock price was $0.85 and its highest was $4.03 in the past 12 months.
What is Pds Biotechnology’s market cap?
Pds Biotechnology’s market cap is $47.97M.
When is Pds Biotechnology’s upcoming earnings report date?
Pds Biotechnology’s upcoming earnings report date is Nov 12, 2025 which is in 39 days.
How were Pds Biotechnology’s earnings last quarter?
Pds Biotechnology released its earnings results on Aug 13, 2025. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.233 by $0.023.
Is Pds Biotechnology overvalued?
According to Wall Street analysts Pds Biotechnology’s price is currently Undervalued.
Does Pds Biotechnology pay dividends?
Pds Biotechnology does not currently pay dividends.
What is Pds Biotechnology’s EPS estimate?
Pds Biotechnology’s EPS estimate is -0.2.
How many shares outstanding does Pds Biotechnology have?
Pds Biotechnology has 47,025,500 shares outstanding.
What happened to Pds Biotechnology’s price movement after its last earnings report?
Pds Biotechnology reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.233. Following the earnings report the stock price went down -5.691%.
Which hedge fund is a major shareholder of Pds Biotechnology?
Currently, no hedge funds are holding shares in PDSB
PDS Biotechnology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.00 (1174.51% Upside)
$13.00 (1174.51% Upside)
Blogger Sentiment
Bullish
PDSB Sentiment 70%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Positive
Last 7 Days ▲ 1.7%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-74.24%
12-Months-Change
Fundamentals
Return on Equity
-156.16%
Trailing 12-Months
Asset Growth
-33.09%
Trailing 12-Months
Company Description
Pds Biotechnology
PDS Biotechnology (PDSB) is a clinical-stage biopharmaceutical company specializing in the development of immunotherapy-based cancer treatments and infectious disease vaccines. Utilizing its proprietary Versamune® technology platform, PDS Biotech focuses on creating novel therapies that activate the immune system to recognize and combat various forms of cancer. The company's primary goal is to bring innovative treatments to market that improve patient outcomes and quality of life.
PDSB Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials and promising data in the oncology segment, particularly with the advancement of VERSATILE-003 and positive results from VERSATILE-002. However, financial challenges were noted, including an increased net loss and a decreased cash balance. While the clinical outlook is promising, financial concerns remain a consideration.View all PDSB earnings summariesPDSB Stock 12 Month Forecast
Average Price Target
$13.00
▲(1174.51% Upside)
Technical Analysis
CytomX Therapeutics
―
Cue Biopharma
―
Sutro Biopharma
―
PMV Pharmaceuticals
―
Acrivon Therapeutics, Inc.
―
Ownership Overview
1.79% Insiders
5.12% Mutual Funds
5.34% Other Institutional Investors
84.13% Public Companies and
Individual Investors